Based on a Johns Hopkins study.

Of note is that among 303 drugs examined in the study, only one, rituximab, a monoclonal antibody preparation that targets antibody-producing B cells, was found to be associated with a substantially increased risk of death compared with medically similar hospitalized COVID-19 patients.

So even as this pandemic becomes endemic we need to do our due diligence.

Rituximab Might Be Only Immunosuppressive Raising Mortality Risk in COVID-19 (